- In a small, prospective study, circulating tumor (ct) DNA positivity is associated with increased risk for relapse in patients with stage III cutaneous melanoma.
Why this matters
- Baseline and postoperative ctDNA detection can inform adjuvant therapy decisions.
- ctDNA was detected in 37% of patients.
- 35% at baseline and 24% postoperatively.
- 54% of patients relapsed.
- Baseline ctDNA detection was associated with decreased relapse-free survival (RFS; HR, 2.9; P=.002) and distant metastasis-free survival (DMFS; HR, 2.9; P=.003).
- Postoperative ctDNA detection was also associated with decreased RFS (HR, 10; P<.001 and dmfs style="list-style-type:circle;">
- HR, 11 (P <.001 for rfs and hr dmfs in multivariate analysis.>
- 99 patients with stage III melanoma and somatic mutations (54% BRAF, 31% NRAS, and 15% TERT promoter, TP53, or KIT) were analyzed for ctDNA and associations with recurrence and survival outcomes.
- The external validation cohort included 29 patients.
- Funding: Australian National Health and Medical Research Council; Cancer Research UK; Wellcome Trust.
- Small patient sample size.